Table 2.
HIV Disease Characteristics and Medical Comorbidities in the HIV+ Sample (n=126)
| Variable | Total HIV+ (n=126) | Younger HIV+ (n=89) | Older HIV+ (n=37) | p |
|---|---|---|---|---|
| HIV Disease Characteristics | ||||
| HIV Infection Duration (years)a,e | 15 [7, 21] | 12 [6, 20] | 17 [9, 21] | 0.05 |
| Current CD4 (cells/ml)b,e | 535 [326, 779] | 547 [357, 814] | 448 [226, 660] | 0.07 |
| Nadir CD4 (cells/ml) | 140 [42, 302] | 199 [54, 350] | 70 [28, 204] | 0.009 |
| Plasma HIV RNA (log10)b,e | 2 [2, 2] | 2 [2, 2] | 2 [2, 2] | 0.47 |
| CSF HIV RNA (log10)c,e | 2 [2, 2] | 2 [2, 2] | 2 [2, 2] | 0.71 |
| Disease Stage | ||||
| AIDS (%) | 60.3 | 55.1 | 73.0 | 0.06 |
| CDC A | 42.1 | 44.9 | 35.1 | |
| CDC B | 23.8 | 25.8 | 18.9 | |
| CDC C | 34.1 | 29.2 | 46.0 | |
| Immunosuppressed (%) | 57.9 | 51.7 | 73.0 | 0.03 |
| Medication Status | 0.75 | |||
| cART (%) | 82.5 | 82 | 83.8 | |
| Non-cART ART (%) | 1.6 | 1.1 | 2.7 | |
| No Current ART | 10.3 | 10.1 | 10.8 | |
| ART Naïve (%) | 5.6 | 6.7 | 2.7 | |
| CPE Rankd,e | 1.5 [1, 2] | 1.5 [1, 2] | 1.5 [1, 2] | 0.83 |
| Medical Comorbidities | ||||
| Hepatitis C Co-infection (%)b | 12.6 | 8.1 | 24.3 | 0.02 |
| Vascular Risk (%)f | 17.5 | 14.6 | 24.3 | 0.21 |
| Hypertension (%)g | 11.9 | 11.2 | 13.5 | 0.77 |
| Hypercholesterolemia (%)g | 4.0 | 3.4 | 5.4 | 0.63 |
| Diabetes Mellitus Type II (%)g | 4.0 | 2.3 | 8.1 | 0.15 |
Note: p-values based on chi-square or Fisher’s exact test and Wilcoxon rank sums test for between-group differences; Immunosuppressed = nadir CD4 < 200; cART = combined antiretroviral therapy; CPE Rank = CNS Penetration-Effectiveness Rank;
a–d
data were available only for a subset of the total HIV+ sample, as follows:
a
n=121,
b
n=124,
c
n=88;
d
n = 106;
e
data presented as medians and interquartile ranges (IQR);
f
vascular risk was defined as having one or more of the cardiovascular conditions listed above percentages;
g
percentages reflect those with current diagnosis